rspНаучно-практическая ревматологияRheumatology Science and Practice1995-44841995-4492IMA-PRESS, LLC10.14412/1995-4484-2008-492rsp-630Research ArticleСтатьиArticlesКачество жизни больных ревматоидным артритом при применении анти-В-клеточной терапии (результаты международных исследований и данные Российского регистра)Quality of life in patients with rheumatoid arthritis receiving anti-В cell therapy (results of international studies and Russia registry)AmirdjanovaV NAmirdjanovaV N-KlimovaN VKlimovaN V-GoryachevD VGoryachevD V-SavenkovaN ASavenkovaN A-НасоновЕвгений ЛьвовичNasonovE L-200815122008466№6 (2008)6468Copyright © Amirdjanova V.N., Klimova N.V., Goryachev D.V., Savenkova N.A., Насонов Е.Л., 20082008Amirdjanova V.N., Klimova N.V., Goryachev D.V., Savenkova N.A., Насонов Е.Л.Amirdjanova V.N., Klimova N.V., Goryachev D.V., Savenkova N.A., Nasonov E.L.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://rsp.mediar-press.net/rsp/article/view/630References<div><p>Quality of life assessment in clinical trials. Ed M.J.Staquet, Oxford University Press, Oxford, New York, Tokyo, 1998, 3</p><p>Quality of life and pharmacoeconomics in clinical trials. Ed. Spilker B., Philadelphia, New York Lippincott-Raven, 1996, 1259-1260.</p><p>Новик А.А, Ионова Т.Н. Руководство no исследованию качества жизни в медицине. М., ОЛМА-ПРЕСС, 2002, 314с.</p><p>Tugwell P., WellsG., MaetzelA. etal. Leflunomide Rheumatoid Arthritis Investigators Group.Clinical improvement as reflected in measures of functional and health-related quality of lifefollowing treatment with leflunomide compared with metotrexate in patients with rheumatoid arthritis: sensivity and relative efficiency to detect a treatment effect in twelve-month, placebo-controlled trial. Anhr. Rheum., 2000,43, 506-514.</p><p>Kosinski М., Zhao S.Z., Dedhiya S. et al. Determining minimally important changes in general and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis. Anhr. Rheum., 2000, 43, 7, 14781487.</p><p>Thuboo J.,Fong K. Y, Ng T.P. et a I Validation of the MOS SF-36 for quality of life assessment of patients with systemic lupus erythematosus in Singapore. J.Rheumatol., 1999, 26, 97-102</p><p>Strand V., Bombardier C., Naetzel A. et al. Use of minimum clinically important differences in evaluating patient responses to treatment of RA. Arthr. Rheum. (suppl.), 2001, 44, S187</p><p>Zhang Z.,Dridges S. L.J. Pathogenesis of rheumatoid arthritis: role of В lymphocytes. Rheum. Dis.Clin.North Am., 2001,27, 335-353</p><p>Сигидин Я.А. Лукина Г.В. Биологическая терапия в ревматологии.М., 2007, 179с</p><p>Leonardo M.J., Edwards J.C. W.,Camridge G.CIinicai outcome in 22 patients with rheumatoid arthritis treated with В lymphocyte depletion.Ann.Rheum.Dis., 2002, 46, 20292033</p><p>Насонов Е.Л. Перспективы применения моноклональных антител к В-лимфоцитам (ритуксимаб) при ревматоидном артрите. Клин.фармакол. терап., 2006, 1-5, 55-58</p><p>Emery P., Fleishmann R., Hlipowich-Sosnowska A.et al. for the DANCER study group. The Efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment. Results of a phase lib randomized, double-blind, placebo-controlled dose-range trial. Arthr. Rheum., 2006, 54, 1390-1400</p><p>Cohen S. B.,Emery P.,Greenwald М. IV. et al. foe the REFLEX Trial Group. Rituximab for the rheumatoid arthritis refractory to anti-tumor necrosis factor therapy. Results of multicenter, randomized, double-blind, placebo-controlled , phase 111 trial evaluating primary efficacy and safety at twenty-four weeks. Arthr. Rheum., 2006, 54, 2793-2806.</p><p>Edwards J.C., Szczepanski L., Szczepanski J.et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N. Engl. J. Med., 2004, 350, 25722581.</p><p>Kielhom A., Bombardieri S., Aultman R. et al. Rituximab improves health-related quality of life as measured by the SF-36: domain score results from the REFLEX study. Ann. Rheum. Dis., 2006, 65 (suppl. 2), 324</p><p>The Working Group on the Rituximab Consensus Statement. Ann. Rheum.Dis., 2007, 66, 143-150</p></div><br /><div><p>Quality of life assessment in clinical trials. Ed M.J.Staquet, Oxford University Press, Oxford, New York, Tokyo, 1998, 3</p><p>Quality of life and pharmacoeconomics in clinical trials. Ed. Spilker B., Philadelphia, New York Lippincott-Raven, 1996, 1259-1260.</p><p>Новик А.А, Ионова Т.Н. Руководство no исследованию качества жизни в медицине. М., ОЛМА-ПРЕСС, 2002, 314с.</p><p>Tugwell P., WellsG., MaetzelA. etal. Leflunomide Rheumatoid Arthritis Investigators Group.Clinical improvement as reflected in measures of functional and health-related quality of lifefollowing treatment with leflunomide compared with metotrexate in patients with rheumatoid arthritis: sensivity and relative efficiency to detect a treatment effect in twelve-month, placebo-controlled trial. Anhr. Rheum., 2000,43, 506-514.</p><p>Kosinski М., Zhao S.Z., Dedhiya S. et al. Determining minimally important changes in general and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis. Anhr. Rheum., 2000, 43, 7, 14781487.</p><p>Thuboo J.,Fong K. Y, Ng T.P. et a I Validation of the MOS SF-36 for quality of life assessment of patients with systemic lupus erythematosus in Singapore. J.Rheumatol., 1999, 26, 97-102</p><p>Strand V., Bombardier C., Naetzel A. et al. Use of minimum clinically important differences in evaluating patient responses to treatment of RA. Arthr. Rheum. (suppl.), 2001, 44, S187</p><p>Zhang Z.,Dridges S. L.J. Pathogenesis of rheumatoid arthritis: role of В lymphocytes. Rheum. Dis.Clin.North Am., 2001,27, 335-353</p><p>Сигидин Я.А. Лукина Г.В. Биологическая терапия в ревматологии.М., 2007, 179с</p><p>Leonardo M.J., Edwards J.C. W.,Camridge G.CIinicai outcome in 22 patients with rheumatoid arthritis treated with В lymphocyte depletion.Ann.Rheum.Dis., 2002, 46, 20292033</p><p>Насонов Е.Л. Перспективы применения моноклональных антител к В-лимфоцитам (ритуксимаб) при ревматоидном артрите. Клин.фармакол. терап., 2006, 1-5, 55-58</p><p>Emery P., Fleishmann R., Hlipowich-Sosnowska A.et al. for the DANCER study group. The Efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment. Results of a phase lib randomized, double-blind, placebo-controlled dose-range trial. Arthr. Rheum., 2006, 54, 1390-1400</p><p>Cohen S. B.,Emery P.,Greenwald М. IV. et al. foe the REFLEX Trial Group. Rituximab for the rheumatoid arthritis refractory to anti-tumor necrosis factor therapy. Results of multicenter, randomized, double-blind, placebo-controlled , phase 111 trial evaluating primary efficacy and safety at twenty-four weeks. Arthr. Rheum., 2006, 54, 2793-2806.</p><p>Edwards J.C., Szczepanski L., Szczepanski J.et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N. Engl. J. Med., 2004, 350, 25722581.</p><p>Kielhom A., Bombardieri S., Aultman R. et al. Rituximab improves health-related quality of life as measured by the SF-36: domain score results from the REFLEX study. Ann. Rheum. Dis., 2006, 65 (suppl. 2), 324</p><p>The Working Group on the Rituximab Consensus Statement. Ann. Rheum.Dis., 2007, 66, 143-150</p></div><br />
The authors declare that there are no conflicts of interest present.